Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth

Status Completed

Clinical Trial Summary

Intrauterine growth restriction (IUGR) is correlated to an abnormal placenta development, with an alteration of the maternal-fetal circulation, coagulation troubles, and apparition of placental infarcts. IUGR represents the third cause of perinatal mortality in France, and is associated to an important morbidity. For birth-weights < 10th percentile of the gestational age, the neonatal death risk is doubled, compared to abnormal weights. In 35% of cases, IUGR is of vascular origin and is included in the broader framework of placental vascular pathology (PVP).

Up to now, studies have focused on the primary or secondary prevention of PVP. Few studies have evaluated the treatment of constituted vascular IUGR. Currently, the management of vascular IUGR is mainly based on active surveillance, or termination of pregnancy. Pathological findings suggest that placental pro-thrombotic phenomena play a role in the constitution of vascular IUGR. Since aspirin is not effective in reducing this type of event, a randomized, open-label study conducted in China compared 14-day treatment with low-molecular-weight heparin (LMWH) versus Dan-Shen (a product not used in France) after diagnosis of IUGR. This trial, including 73 patients, showed a significant improvement in average growth kinetics in the LMWH group. The mean birth weight was 2877 g in the heparin group and 2492 g in the Dan-Shen group (p <0.0001). However, no data were provided concerning the number of newborns with a birth weight <10th percentile, i.e. the risk of morbidity and mortality, or complications occurring. Due to the lack of reliable data, LMWH are not included in the currently recommended therapeutic strategy for vascular IUGR.

The studies in IUGR reported to date mainly focused on primary or secondary prevention in women at risk of PVP, assessing the value of aspirin, which showed only a modest effect. No effective therapeutic strategy is available to treat patients with constituted vascular IUGR, a situation where LMWH should be more effective than antiplatelets given the vascular context.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fetal Growth Retardation

Clinical Trial Details

NCT number	NCT02672566
Study type	Interventional
Source	Centre Hospitalier Universitaire de Saint Etienne
Contact
Status	Completed
Phase	Phase 3
Start date	July 22, 2016
Completion date	January 22, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05899101` - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed	`NCT04502823` - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler	N/A
Not yet recruiting	`NCT03625518` - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes	Early Phase 1
Completed	`NCT05176041` - SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
Completed	`NCT02379728` - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth	N/A
Completed	`NCT01695070` - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Completed	`NCT04289350` - Day to Day Variation in Fetal Heart Rate Variability
Recruiting	`NCT03662178` - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting	`NCT05023161` - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed	`NCT02590536` - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction	Phase 3
Not yet recruiting	`NCT05029778` - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve	Phase 4
Recruiting	`NCT05576207` - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)	N/A
Active, not recruiting	`NCT05160649` - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed	`NCT02280031` - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.	Phase 2
Recruiting	`NCT04389099` - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting	`NCT06039319` - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting	`NCT05651347` - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction	Phase 3
Recruiting	`NCT02336243` - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders	Phase 3
Active, not recruiting	`NCT01594463` - Routine Ultrasound Screening in the Third Trimester	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction — GROWTH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms